Literature DB >> 14508395

Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions.

Holly Zhou1, Cheryl M Coffin, Sherrie L Perkins, Sheryl R Tripp, Michael Liew, David H Viskochil.   

Abstract

This study investigates differences in expression of the cell cycle/growth activation markers p53, p16, and p27, and their relationship with nerve sheath cell and proliferation markers among plexiform neurofibromas (PNF), NF1-related and non-NF1 MPNSTs of different histologic grades and between benign-appearing and malignant areas in the MPNSTs associated with PNFs. Formalin-fixed, paraffin-embedded archival tissue from PNFs and MPNSTs were immunostained using the avidin-biotin-complex method with antibodies to S-100 protein (S-100), Leu7 (CD57), CD34, p16, p27, p53, Mib-1, and topoisomerase II-alpha (TopoIIalpha), with appropriate controls. All PNFs and most low-grade MPNSTs displayed diffuse or focal reactivity for S-100, Leu7, CD34, p16, and p27 and negative reactivity for p53, Mib-1, and TopoIIalpha. Most high-grade MPNSTs displayed decreased or negative reactivity to S-100, Leu7, CD34, p16, and p27 but increased reactivity to p53 (59%), Mib-1 (72%), and TopoIIalpha (72%). In addition, combined nuclear and cytoplasmic (nucleocytoplasmic) p27 staining, which was not seen in the PNF or low-grade MPNST, was observed in 33% of high-grade MPNSTs. These findings suggest that p53, p16, and p27 may be involved in tumor progression in the PNF-MPNST sequence. However, alterations in p53, p16, and p27 do not distinguish between low-grade MPNST and PNF, including PNF adjacent to high-grade MPNST. Although p53, p16, and p27 are unlikely to be reliable markers for early detection of tumor progression in MPNST, p53 reactivity was more frequent in NF1-associated high-grade MPNST and appeared to be a marker for high tumor grade. Combining immunohistochemical stains with histologic grading with careful examination of mitotic activity may provide insight into the progression of peripheral nerve sheath tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508395     DOI: 10.1097/00000478-200310000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  34 in total

Review 1.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

2.  Sox10--a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors.

Authors:  Markku Miettinen; Peter A McCue; Maarit Sarlomo-Rikala; Wojciech Biernat; Piotr Czapiewski; Janusz Kopczynski; Lester D Thompson; Jerzy Lasota; Zengfeng Wang; John F Fetsch
Journal:  Am J Surg Pathol       Date:  2015-06       Impact factor: 6.394

Review 3.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

4.  The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.

Authors:  Christine S Higham; Eva Dombi; Aljosja Rogiers; Sucharita Bhaumik; Steven Pans; Steve E J Connor; Markku Miettinen; Raf Sciot; Roberto Tirabosco; Hilde Brems; Andrea Baldwin; Eric Legius; Brigitte C Widemann; Rosalie E Ferner
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

Review 5.  Molecular targets for NF1-associated malignant peripheral nerve sheath tumor.

Authors:  Lama Binobaid; Michal M Masternak
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-27

Review 6.  Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers.

Authors:  Markku Miettinen
Journal:  Histopathology       Date:  2013-11-28       Impact factor: 5.087

7.  Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Authors:  Syed J Kazmi; Stephanie J Byer; Jenell M Eckert; Amy N Turk; Richard P H Huijbregts; Nicole M Brossier; William E Grizzle; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Am J Pathol       Date:  2013-01-13       Impact factor: 4.307

8.  Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors.

Authors:  Helge R Brekke; Matthias Kolberg; Rolf I Skotheim; Kirsten S Hall; Bodil Bjerkehagen; Björn Risberg; Henryk A Domanski; Nils Mandahl; Knut Liestøl; Sigbjørn Smeland; Håvard E Danielsen; Fredrik Mertens; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2009-01-30       Impact factor: 12.300

9.  Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis.

Authors:  Stephanie N Brosius; Amy N Turk; Stephanie J Byer; Nicole M Brossier; Latika Kohli; Amber Whitmire; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Acta Neuropathol       Date:  2014-04       Impact factor: 17.088

10.  Malignant peripheral nerve sheath tumor in neurobifromatosis type-1: two case reports.

Authors:  Christos Kosmas; George Tsakonas; Katerina Evgenidi; Argyris Gassiamis; Lefkothea Savva; Nikolaos Mylonakis; Athanasios Karabelis
Journal:  Cases J       Date:  2009-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.